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marrow-derived tissue repair cells and placebo in
patients with critical limb ischemia
Richard J. Powell, MD,a Anthony J. Comerota, MD,b Scott A. Berceli, MD,c Raul Guzman, MD,d
Timothy D. Henry, MD,e Edith Tzeng, MD,f Omaida Velazquez, MD,g William A. Marston, MD,h
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Ann Arbor, Mich
Objectives: Cell therapy is a novel experimental treatment modality for patients with critical limb ischemia (CLI) of the
lower extremities and no other established treatment options. This study was conducted to assess the safety and clinical
efficacy of intramuscular injection of autologous tissue repair cells (TRCs).
Methods: A prospective, randomized double-blinded, placebo controlled, multicenter study (RESTORE-CLI) was
conducted at 18 centers in the United States in patients with CLI and no option for revascularization. Enrollment of 86
patients began in April 2007 and ended in February 2010. For the prospectively planned interim analysis, conducted in
February 2010, 33 patients had the opportunity to complete the trial (12 months of follow-up), and 46 patients had
completed at least 6 months of follow-up. The interim analysis included analysis of both patient populations. An
independent physician performed the bone marrow or sham control aspiration. The aspirate was processed in a closed,
automated cell manufacturing system for approximately 12 days to generate the TRC population of stem and progenitor
cells. An average of 136  41  106 total viable cells or electrolyte (control) solution were injected into 20 sites in the
ischemic lower extremity. The primary end point was safety as evaluated by adverse events, and serious adverse events as
assessed at multiple follow-up time points. Clinical efficacy end points included major amputation-free survival and time
to first occurrence of treatment failure (defined as any of the following: major amputation, death, de novo gangrene, or
doubling of wound size), as well as major amputation rate and measures of wound healing.
Results: There was no difference in adverse or serious adverse events between the two groups. Statistical analysis revealed
a significant increase in time to treatment failure (log-rank test, P  .0053) and amputation-free survival in patients
receiving TRC treatment, (log-rank test, P  .038). Major amputation occurred in 19% of TRC-treated patients
compared to 43% of controls (P  .14, Fisher exact test). There was evidence of improved wound healing in the
TRC-treated patients when compared with controls at 12 months.
Conclusions: Intramuscular injection of autologous bone marrow-derived TRCs is safe and decreases the occurrence of
clinical events associated with disease progression when compared to placebo in patients with lower extremity CLI and no
revascularization options. ( J Vasc Surg 2011;54:1032-41.)
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0Approximately 1.1 million Americans suffer from periph-
eral artery disease (PAD), which is associated with a 5-year
cardiovascular death risk of 20% to 30%.1 Critical limb isch-
emia (CLI) is the severest form of PAD defined by severely
impaired hemodynamics and chronic ischemic rest pain, ul-
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LI is high. Up to 20% of patients with CLI will die within the
rst 6 to 12 months; 2-year, 5-year, and 10-year mortality
ates are approximately 35%, 70%, and 100%, respectively. As
any as 40% to 50% of patients will undergo major limb
mputation within 6 to 12 months.2 The ability of this elderly
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Volume 54, Number 4 Powell et al 1033patient population with many associated comorbidities to
successfully rehabilitate and maintain an independent living
status following major limb amputation is poor.
The treatment of CLI patients is multidisciplinary.3
Underlying atherosclerosis is treated pharmacologically
with lipid reduction, antiplatelet, and antihypertensive thera-
pies. Wound care and surgical debridement is also integral to
patient care.4 Revascularization continues to be the mainstay
of therapy, and this includes either open surgical procedures
or percutaneous endovascular approaches.
For a substantial number of patients effective revas-
cularization is not possible, due to location or extent of
the disease or associated comorbidities precluding open
surgery. Patients with CLI, who are unable to undergo
successful revascularization, currently have no effective
treatment options. There are currently no Food and
Drug Administration (FDA)-approved therapies for
CLI. Therapy for this “no-option” CLI patient popula-
tion is limited to management of the associated comor-
bidities with intensive wound care, pain control, and
eventual amputation of the limb. Thus, the no-option
CLI patient represents a population with a serious and
life-threatening disease with an unmet medical need.
Given the limitations of current therapies and high rate
of mortality, CLI quality of life in this patient population
has been likened to terminal cancer.5
Biologic regenerative therapies, including stem cell
therapy (autologous and allogeneic) and gene transfer are
currently undergoing clinical investigation. In several clin-
ical studies, administration of bone marrow cells (BMC)
appears to have improved critical limb ischemia patient
outcomes.5-9 In adults, bone marrow is the reservoir for
stem and progenitor cells that can differentiate into cells
that repair or generate new blood vessels. Administration of
cells by injection directly into the ischemic tissue has devel-
oped as a potential strategy to improve limb perfusion and
limb salvage in the ischemic limb.
It is not clear which subsets of BMCs are optimal for
treating CLI. Animal studies have demonstrated that vari-
ous subsets of bone marrow cells are active in improving
vascularization in limb ischemia models.9 This suggests
that a combination of cell types may provide enhanced
benefit, by providing precursors of various lineages or by
the interactions between them that may drive differentia-
tion and proliferation. Tissue repair cells (TRCs) expanded
from autologous bone marrow are a mixture of cell types.10
They are composed of the same mesenchymal and hemato-
poietic progenitor cells found in bone marrow but have a
greater number of certain cells, such as monocytes/macro-
phages, that have been reported to be central to neovascu-
larization.9 In vitro, the TRC production process sup-
ports growth of stem cells, progenitors and mature cells
in mesenchymal, endothelial and myeloid lineages, while
reducing lymphoid and erythroid precursors.10,11 The
RESTORE-CLI trial is a randomized, double-blind
multi-center phase II study comparing intramuscular
injection of TRCs against placebo in affected limbs of aatients with CLI in patients without revascularization
ptions. Interim safety and efficacy analyses are reported.
ETHODS
tudy design
The study “Use of Tissue Repair Cells (TRCs-Autolo-
ous Bone Marrow Cells) in Patients with Peripheral Arte-
ial Disease to Treat Critical Limb Ischemia” (RESTORE-
LI) is a prospective, randomized, double-blinded, placebo-
ontrolled multicenter study that compares intramuscular
njections of expanded autologous bone marrow cells (“tis-
ue repair cells” or TRCs) that are suspended in physiolog-
cal electrolyte solution with injections of the same electro-
yte solution without cells in patients with lower extremity
LI. The study was sponsored by Aastrom Biosciences Inc
n Ann Arbor, Michigan. The protocol was reviewed by the
enter of Biologics Evaluation and Research (CBER) of
he Federal FDA and the institutional review boards of the
articipating centers. All participants provided written vol-
ntary consent. An independent Data Safety Monitoring
oard (DSMB), consisting of three expert physicians and
ne statistician who were not involved in any other aspect
f the study, monitored the safety of participants in the
tudy according to the DSMB charter specifically devel-
ped for RESTORE-CLI.
Eligible patients were men and women 18 to 90 years
f age with a diagnosis of CLI of the lower extremities
efined as persistent, recurring ischemic rest pain for at least
weeks and/or ulceration or gangrene of the foot or toe
ith absent palpable pedal pulses with toe systolic pressure
50 mm Hg or ankle systolic pressure 70 mm Hg.
atients with flat or barely pulsatile pulse volume recording
PVR) and higher systolic blood pressures could be in-
luded based on sponsor review. Patients with infrainguinal
cclusive disease without acceptable options for revascular-
zation as determined by the site principle investigator were
onfirmed by angiographic imaging or color flow duplex
ltrasound within 6-months prior to randomization were
ligible. Establishment of controlled blood pressure with
ntihypertensive therapy as necessary, adequate antiplate-
et, and statin therapy was required prior to entry.
Main exclusion criteria were HbA1c 10%; known
ortoiliac disease with50% stenosis; wound with exposed
endon or bone; known failed ipsilateral revascularization
rocedure within 2 weeks prior to randomization (defined
s failure to restore adequate circulation, ie, the procedure
id not achieve an increase in ankle-brachial Index (ABI) of
.15 or more, substantial improvement in PVR, or clinical
mprovement); previous amputation of the talus or above in
he target limb; infection of the involved extremity mani-
ested by fever, purulence, and severe cellulitis; and active
et gangrenous tissue.
Patients were centrally randomized 2:1 (treatment:
ontrol). Visits were scheduled on day minus 14 (bone
arrow or sham aspiration), day 0 (injection), days 3 and 7,nd months 3, 6, 9, and 12.
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October 20111034 Powell et alEnrollment began at 22 clinical sites in the United
States in April 2007 with 18 actually randomizing patients.
The planned study population size was originally up to 150
patients. By November 2009, 33 patients had the oppor-
tunity to complete the trial (the 12-month follow-up visit)
and were included in a prospectively planned interim anal-
ysis. The interim analysis was expanded to include 13
additional patients that had completed 6 months of
follow-up at that time. Only the set of 33 patients complet-
ing 12 months and the set of 13 patients completing 6
months of follow-up by November 2009 were unblinded
and included in the interim analysis and reported. Enroll-
ment has been subsequently halted, and all enrolled pa-
tients will be followed until completing the 12 month
efficacy end point.
Bone marrow aspiration, TRC production, and
intramuscular injection
An independent physician (other than the physician
performing TRC injections) aspirated approximately 50
mL bone marrow from the posterior iliac crest. Control
patients underwent a sham aspiration that involved the
insertion of an aspiration needle at the iliac crest without
penetration of the iliac periosteum. The aspirate was
shipped overnight to Aastrom Biosciences Inc for TRC
production. Patients were dropped from the study if the
bone marrow was determined to be unsuitable for ex vivo
processing due to insufficient mononuclear cell number or
if the TRC product did not meet production specifications
for sterility and number of total and CD90 viable cells. In
addition, patients could drop out between randomization
and aspiration and treatment due to interceding medical
events.
The TRC product was generated in a single-pass
perfusion biochamber over approximately 12 days and
then transported to the clinical site in a shipping con-
tainer designed to maintain hypothermic storage condi-
tions (between 0 and 12°C).10 TRCs are a mixture of
nucleated cells cultured from the patient’s bone marrow
with high viability. TRCs are primarily composed of two
cell phenotypes: mesenchymal stem and progenitor cells
defined by the CD90 cell surface marker, and hemato-
poietic and endothelial stem and progenitor cells, de-
fined by the CD45 cell surface marker. The overall cell
viability as measured by membrane integrity by dye
exclusion was 70%. The cells are suspended in a physiolog-
ical solution of HypoThermosol (BioLife Solutions, Bothell,
Wash) and Isolyte (B. Braun, Bethlehem, Pa) supplemented
with 0.5% human serum albumin (HSA) in a volume be-
tween 5.8 and 8.4 mL. Characteristics of TRCs from pa-
tients in the RESTORE-CLI interim analysis are presented
in the Results section.
An average of 136 million total viable TRCs, of which
25 million were CD90, or electrolyte (control) solution
was injected into 20 sites in the ischemic lower extremity.
Injection sites were mapped by marking four circumferen-
tial linear bands around the lower third of the thigh, the
greatest diameter of the patient’s calf, and at one location broximal and one distal to greatest calf diameter; five injec-
ions of 0.5 mL were given along each band, at least 2.0 cm
part and 0.5 inches into the muscle, to include all muscle
roups. The majority of patients also had four injections
laced in the intermetatarsal spaces either on the dorsal or
lantar surface. In this case, only four injections per linear
and were administered.
tudy end points
Safety evaluations. The primary end point of the
tudy was safety, which included adverse events, aspiration
ite assessment, injection toxicities, and injection site assess-
ents. Amputation rates and wound healing, while also
afety end points, are described below in the Efficacy eval-
ations section.
Safety was assessed continually throughout the study
ia direct evaluation (including physical examination, vital
igns measurement and electrocardiography) and by spon-
aneous reporting by the patient during study visits or
elephone contacts. The DSMB reviewed safety data on a
uarterly basis.
Efficacy evaluations. The efficacy of TRC treatment
as assessed by secondary end points. Principal efficacy
easures included time to first occurrence of treatment
ailure, amputation-free survival, incidence of major ampu-
ation, and wound healing. Study investigators made am-
utation decisions independently based on their clinical
udgment.
The composite treatment failure end point was com-
rised of the following events: major amputation, death,
oubling of wound total surface area from baseline (day 0),
r occurrence of de novo gangrene. Major amputation was
efined as amputation at or above the talus on the limb
eceiving injections. For a given patient, the time to first
ccurrence of treatment failure was defined as the earliest
ay at which any one of the treatment failure events oc-
urred. For patients who did not experience any of the
reatment failure events, their last day in the study was used
o calculate event-free duration.
The duration of amputation-free survival was defined as
he first day on which a major amputation or death was
eported. For patients who did not experience a major
mputation or death, their last day in the study was used to
etermine the event-free duration.
Wound healing was evaluated according to three sepa-
ate assessments: severity using the Wagner Wound Scale,
omplete wound healing, and total surface area of wounds.
agner classification is useful to measure wound depth
hereas total surface area is useful to measure changes in
ore superficial Wagner 1 and 2 classification wounds.
nly wounds present at entry into the study were evaluated
y the Wagner Wound Scale and for complete wound
ealing. The total wound surface area was calculated as the
um of the surface area of each individual wound. For a
ound that appeared after the baseline evaluation, the
aseline surface area for that wound was defined as zero.
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As a phase II trial the primary purpose of the trial was
exploratory. The planned sample size was based on assum-
Fig 1. Patient flow diagram (based on i
Table I. Patient disposition for RESTORE-CLI interim
analysis – 6-month population
Parameter TRC Control
Randomized, n (%) 32 (100) 14 (100)
Aspirated, n (%) 32 (100) 14 (100)
Treated, n (%) 32 (100) 14 (100)
Withdrew after treatment, n (%) 7 (22) 1 (7)
Reason for withdrawal, n (%)
Withdrew consent 1 (3) 0 (0)
Death 1 (3) 1 (7)
Did not return to clinic 3 (9) 0 (0)
Loss to follow-up 1 (3) 0 (0)
Amputation of treated leg 1 (3) 0 (0)
Completed, n (%) 16 (50) 10 (71)
Continuing follow-up, n (%) 9 (28) 3 (21)
TRC, Tissue repair cells.ing 100 TRC patients and 50 control patients and a control womposite primary event rate of 65% at 6 months with  
.05, 2-sided, then there would be over 80% power to
etect a 30% treatment effect (a TRC event rate of 39%).
Safety and efficacy data were summarized for the ran-
omized and treated patient populations at 6 and 12
onths posttreatment. The 6- and 12-month populations
ere defined as all study participants with the opportunity
o complete 6 or 12 months of follow-up, respectively, as of
ovember 2009.
Amputation-free survival and time to first occurrence of
reatment failure were both summarized using Kaplan-
eier plots by treatment group; the P value from the
og-rank test was provided for descriptive purposes. Major
mputation rates at 6 and 12 months were analyzed using
isher exact test.
The last-observation-carried-forward (LOCF) method
as used for wounds removed due to an amputation at or
bove the wound location, for total wound surface area and
agner Wound Scale category.
Measurements of wound severity were based on the
agner Wound Scale categories. Statistical evaluations
analysis data up to November 2009).ere based on the most severe wound (highest Wagner
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October 20111036 Powell et alscore) present at day 0. The number and percent of patients
in each Wagner scale category for each time point as well as
the number and percent of patients with improving
wounds, were based on the reduction of the Wagner score
from baseline. Fisher exact test was used to analyze differ-
ences in the proportion of patients experiencing wound
improvement between groups.
Complete wound healing was summarized as the num-
ber and percent of patients with wounds present at baseline
whose wounds were healed at a given time point (wound
size of 0 cm and Wagner score of 0 for each wound). Total
wound surface area and change from baseline were summa-
rized by descriptive statistics.
RESULTS
Patient enrollment and characteristics
The trial patient flow is shown in Fig 1. The disposition
of the 46 patients in the 6-month population is shown in
Table I. There were seven treatment group withdrawals
due to withdrawal of consent (one patient), death (one
patient), not returning to clinic for mandated assessments
(three patients), loss to follow-up (one patient), and ampu-
tation of the injected leg (one patient; this was not a
protocol allowable reason for withdrawal). In the control
group, the one withdrawal was due to death. All patients
who withdrew were included in all efficacy and safety
analyses. Five of the seven withdrawals in the treatment
Table II. Patients withdrawn: Time in study, reason for w
Treatment
Study day of
withdrawal Reason for withd
TRC 63 Other: Amputation of in
TRC 407; Last relevant data
(labs) reported at
month 9/day 259
Investigator discretion: M
unable to return
TRC 210 Other: Lost to follow-up
letter sent
TRC 197; Last relevant data
(labs) reported at
month 3/day 97
Other: Patient did not re
clinic; called 3 times; c
sent
TRC 207 Withdrew consent
TRC 132 Death
TRC 380; Last relevant data
(labs) reported at
month 9/day 254
Other: Patient did not re
9
Control 37 Death
TRC, Tissue repair cells.group occurred after the 6-month time point. Four of seven fithdrawals in the treatment group experienced a treat-
ent failure efficacy end point prior to withdrawal. The one
ontrol withdrawal also experienced a treatment failure
fficacy end point prior to withdrawal. The time point,
easons for patient withdrawal, and outcomes are shown in
able II. Baseline characteristics for the 46 patients are
hown in Table III. There was no significant difference
etween the treatment and control group in any of the
emographic parameters.
nalysis of bone marrow aspirate and TRC
henotype
The cell surface phenotype of cells from both the bone
arrow aspirates and the TRC product was assessed by flow
ytometry in 19 of the patients that received TRCs. The
esults, presented in Fig 2, are consistent with established
henotypic differences between unprocessed bone marrow
ononuclear cells and culture expanded TRCs.10 The total
umber of cells was decreased by more than half primarily
ue to loss of non-proliferative hematopoietic cells, includ-
ng mature lymphocytes and granulocytes, which is re-
ected in the marked decrease in the number CD45 cells.
n contrast, the CD90 mesenchymal cell population was
xpanded about 25-fold from 1 to 25 million cells. Mono-
ytes, as defined by CD14 expression, were expanded by
pproximately twofold. The specific population of auto-
uorescent CD14 activated macrophages increased 12-
awal, and contribution to efficacy data
l Additional information
d leg Below knee above talus amputation on treated side
on day 31. No wound data reported or other
events contributing to treatment failure
composite.
d visit 9; No amputations reported. Wound data reported
through month 9. No other events contributing
to treatment failure composite.
ified Above knee amputation on treated side on day 101.
Wound data reported through day 7. No other
events contributing to treatment failure composite.
to
ed letter
No amputations were reported. No wound data
reported. No events contributing to treatment
failure composite.
Above knee amputation on treated side on day 32.
Wound data reported through day 7. No other
events contributing to treatment failure composite.
Adverse event of cardiac failure congestive began on
day 114 and ended in death on day 132. No
amputations were reported. Wound data reported
through month 3. Death was event contributing
to treatment failure composite.
for visit Wound data reported through month 9. No events
contributing to treatment failure composite.
Adverse event of hypovolemic shock began on day
37 and ended in death on the same day. Wound
data reported at baseline only.ithdr
rawa
jecte
isse
; cert
turn
ertifi
turnold, from 0.75 to more than 9 million. There was no
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Volume 54, Number 4 Powell et al 1037significant difference between diabetic and non-diabetic
subjects in the ratio of TRCs to bone marrow aspirate cells,
or in any of the cell subsets included in Fig 2 by t test with
significance level  0.05 (data not shown).
Safety outcomes
A summary of overall adverse events (AEs) is shown in
Table IV. Nearly all patients reported AEs; the proportion
of AEs in TRC-treated and control groups was consistent
with the 32 to 14 patient randomization. The percentage of
patients with serious adverse events (SAEs) was similar
between the groups: 44% in TRC-treated and 57% in
control patients. There was 1 death each in the TRC-
treatment and in the control groups; neither was consid-
ered related to treatment. AEs reported by a total of 4 or
more patients in the 6-month population are listed in Table
V. Bone marrow aspiration and injection site toxicities were
minimal.
Most severe AEs were determined by investigators to
be “unrelated” or “unlikely related” to treatment, but
Table III. Patient demographics for RESTORE-CLI
interim analysis – 6-month population
Baseline parameter
TRC Control P
valueaN  32 N  14
Gender, n (%) .17
Male 25 (78) 8 (57)
Female 7 (22) 6 (43)
Age, years .76
Mean (SD) 68.8 (12.4) 65.9 (13.4)
Smoking status, n (%) .61
Never 5 (16) 2 (14)
Current 7 (22) 5 (36)
Past 20 (63) 7 (50)
Alcohol consumption, n (%) .44
Never 7 (22) 5 (36)
Current 15 (47) 4 (29)
Past 10 (31) 5 (36)
BMI .19
Mean (SD) 27.3 (5.0) 28.8 (5.8)
Creatinine, mg/dL .88
Mean (SD) 1.21 (0.38) 1.07 (0.32)
Prior amputation below
talus of treated limb, n
(%)
5 (16) 2 (14) 1.00
Known diabetes, n (%) 14 (44) 9 (64) .34
Known on dialysis, n (%) 0 (0) 0 (0) NA
GFR, n (%) NA
30 0 (0) 0 (0)
30 32 (100) 14 (100)
ABIb .50
N 26 10
Mean (SD) 0.4 (0.2) 0.4 (0.2)
ABI, Ankle-brachial index; BMI, body mass index; GFR, glomerular filtra-
tion rate; NA, not applicable; SD, standard deviation; TRC, tissue repair
cells.
aP values from Fisher exact test for count data, from t-test for continuous
data.
bNot all patients had ABI evaluations, since protocol allowed either ABI, toe
pressure, or waveform measurement at baseline.rather to the underlying disease. Two events in treated watients were considered “possibly related” to TRC treat-
ent. One patient experienced moderate cellulitis in the
reated limb after bone marrow aspiration but prior to TRC
njections. The second patient had a severe localized infec-
ion of the first toe of the treated limb recorded on study
ay 34 that resolved by study day 63.
fficacy outcomes
All analyses were based on the intention to treat
-month or 12-month populations, respectively. It should
e noted that RESTORE-CLI was not statistically powered
o demonstrate efficacy of TRC therapy. The interim effi-
acy analysis was designed to demonstrate feasibility and
upport the statistical design of larger clinical trials. The
tudy was stopped early following the 6-month interim
nalysis due to a positive efficacy signal and the sponsor’s
lan to develop the phase III program.
Time to treatment failure. Treatment failure was
efined as a composite end point of major amputation,
eath, doubling of wound size from baseline, or de novo
ccurrence of gangrene. Statistical analysis of this popula-
ion revealed that the time to first occurrence of treatment
ailure was significantly longer in TRC-treated patients
ompared with control patients (Fig 3, log-rank test, P 
0053). Differentiation between the two groups appeared
ithin the first 100 days of follow-up and was maintained
hrough the remainder of the study. In the 6-month pop-
lation, 11 of 14 control patients (79%) and 13 of 32
RC-treated patients (41%) failed treatment by this defini-
ion (Fisher exact test, P  .026). The etiology of the first
ccurrence of treatment failure, as well as the total number
f patients experiencing each type of failure, is listed in
able VI.
Amputation-free survival. Analysis of the 6-month
opulation revealed that amputation-free survival was sig-
ificantly longer in the TRC-treated patients compared
ith control patients (Fig 4, log-rank test, P  .038). As
ith time to treatment failure, differentiation between the
istributions appeared within the first 50 days of follow-
p and was maintained throughout the study. Median
mputation-free survival times for control and TRC-treated
atients had not been reached.
Major amputation. For the 6-month population at
onth 6, major amputation occurred in 43% of the control
roup compared with 19% in the treatment group (P .14;
isher exact test). There was no difference in above vs
elow the knee amputation between the groups. Below the
nee amputation occurred in 66% of patients requiring
ajor amputation in each group. For the 12-month popu-
ation, major amputation occurred in 36% of the control
roup compared with 18% in the treatment group at both
onths 6 and 12 (P  .39; Fisher exact test).
Wound healing. Thirty-three patients had evaluable
ounds at baseline that allowed efficacy assessment. Com-
lete wound healing, defined as a Wagner score of 0 and
ound size of 0 cm for each wound, was summarized as the
ercent of patients with wounds present at baseline for
hom all wounds have healed at a given time point. Com-
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October 20111038 Powell et alplete wound healing is shown for the 12-month patient
population with wounds present at baseline in Fig 5. For
the 12-month population at month 6, there were no differ-
ences in complete wound healing between the treatment
and control groups. At month 12, complete wound healing
was present in a greater percentage of the treatment group
Fig 2. Phenotypic analysis of bone marrow aspirate an
analysis was performed on aspirate samples before autom
Patients that had samples with complete phenotypic a
(n  19). Figures above the bars indicate the average nu
Table IV. Overview of safety – 6-month population
Parameter
TRC Control
N  32 N  14
Patients reporting adverse events, n (%) 30 (94) 14 (100)
Number of adverse events 154 64
Patients with serious adverse events, n (%) 14 (44) 8 (57)
Number of serious adverse events 21 15
Number of deaths 1 1
Withdrawals due to adverse events (not
including deaths), n (%) 0 (0) 0 (0)
TRC, Tissue repair cells.
Table V. Most frequently reported adverse events – 6-
month population
Preferred term, n (%)
TRC Control
N  32 N  14
Any adverse event 30 (94) 14 (100)
Pain in extremity 13 (41) 3 (21)
Skin ulcer 8 (25) 1 (7)
Nausea 5 (16) 3 (21)
Gangrene 4 (13) 3 (21)
Cellulitis 2 (6) 4 (29)
Diarrhea 4 (13) 1 (7)
Procedural pain 4 (13) 1 (7)
Localized infection 2 (6) 2 (14)
TRC, Tissue repair cells.(31%) compared with the control group (13%); these dif- terences were not statistically significant. Other measures of
ound healing (Wagner Wound Scale, total wound surface
rea) did not show significant differences between groups.
ISCUSSION
RESTORE-CLI is the first placebo-controlled autolo-
ous stem cell trial to use expanded bone marrow mono-
uclear cells (TRCs) to treat no-option CLI patients. The
tudy is designed to evaluate hard clinical end points that
re consistent with recent recommendations for the con-
uct of trials in CLI3 rather than surrogate end points. It is
ouble-blinded and studies a larger subject population than
reviously reported cellular therapy studies in CLI. Interim
nalysis of this phase II trial has demonstrated that TRC
herapy is safe and yields potential improvement in efficacy
utcomes.
A unique feature of this autologous stem cell therapy is
hat TRCs are generated in a closed and automated culture
ystem that expands the number of mesenchymal and
onocytic stem and progenitor cells.10 This enrichment is
specially pronounced in cells that express the surface mark-
rs CD90, reflecting mesenchymal lineage, and CD14, a
arker of monocyte/macrophage lineage. The increase in
D14 cells is almost entirely within the subset of activated
utofluorescent cells. The TRC culture expansion process
hus increases the number of both lineages of cells reported
o be effective in treating CLI.
The precise mechanism(s) of action for TRCs in CLI
re not yet established. It is unclear if the injected cells are
irectly involved in the angiogenic process or act as cyto-
ine factories releasing multiple different growth factors
hat have a paracrine effect.
There are several putative mechanisms of activity of cell
herapy in CLI. These mechanisms include (1) increased
e repair cell (TRC) product samples. Flow cytometric
single-pass perfusion culture and on the TRC products.
es for both aspirate and TRC samples were included
of cells in millions.d tissu
ated
nalysissue vascularity; (2) increased tissue microperfusion at the
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Volume 54, Number 4 Powell et al 1039capillary level; (3) remodeling of fibrotic tissues to allow
new capillary growth or increase interstitial fluid flow; and
(4) modulation of the inflammatory response program
from tissue destruction to wound healing. Since a combi-
nation of these mechanisms may be synergistic, the mixture
of precursor cells in TRCs that includes mesenchymal,
endothelial, and inflammatory cell precursors, may be im-
portant in their therapeutic function. For instance, the
presence of CD14 macrophages may promote the disso-
lution of extracellular matrix in the perivascular interstitial
space and thus enhance vessel sprouting by endothelial
precursors.9
The study was performed primarily to assess safety and
Fig 3. Kaplan-Meier survival plot of time to first occu
amputation, doubling of wound total surface area, occurr
control group patients within the first 100 days; median
censored for the analysis. In the tissue repair cell (TRC)
reached, with 19 of 32 patients censored for the analysis. C
of subjects at risk in the TRC-treated group were 32 at d
Number of subjects at risk in the control group were 14
Table VI. Occurrence of composite treatment failure end
Patient treatment group TRC (N  32)
Number that failed
treatment 13 (41%)
Composite end point
component N(%)
Patients experiencing
as first event ex
Major amputation 6 (19%)
Death 1 (3%)
Doubling in wound size 4 (13%)
De novo gangrene 2 (6%)
TRC, Tissue repair cells.tolerability of TRC therapy. As expected in an autologous well therapy, the administration of TRCs was safe and well
olerated. The number of patients reporting SAEs was
imilar in the TRC-treated group compared to the control
roup. RESTORE-CLI was not statistically designed for
emonstration of efficacy, which was a secondary aim of the
rial. In addition, the interim analysis reported here was
erformed in only 46 of the 86 subjects. Despite these
imitations, the interim analysis revealed statistically signif-
cant differences in time to first occurrence of treatment
ailure and amputation-free survival between TRC-treated
nd control subjects. Wound healing differences, thought
ot statistically significant, favored TRC-treated patients at
he 12-month but not the 6-month time point, consistent
e of treatment failure, a composite end point of major
of de novo gangrene, or death. Most events occurred in
to treatment failure was 60 days with 3 of 14 patients
ed group, the median time to treatment failure was not
red observations are indicated by “” symbols. Number
nd 26 at day 100 and 16 at day 200 and 13 at day 300.
0 and 5 at day 100 and 4 at day 200 and 2 at day 300.
t
Control (N  14)
11 (79%)
l patients
cing event
Patients experiencing
as first event
Total patients
experiencing event
(19%) 4 (29%) 6 (43%)
(3%) 1 (7%) 1 (7%)
(19%) 4 (29%) 6 (43%)
(13%) 2 (14%) 2 (14%)rrenc
ence
time
-treat
enso
ay 0 apoin
Tota
perien
6
1
6
4ith a durable clinical benefit.
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various stem cell therapy techniques. Gene therapy trials
using hepatocyte growth factor (HGF),12,13 vascular
endothelial growth factor (VEGF),14,15 or fibroblast
growth factor (FGF)16,17 have been performed. Early
phase II trials using either FGF or HGF have shown
potential in the treatment of CLI and are currently in
pivotal trials. Potential advantages of gene therapy in
CLI include an “off the shelf” therapy that can be
Fig 4. Kaplan-Meier survival plot of amputation-free su
the first 50 days; median time to treatment failure was no
the tissue repair cell (TRC)-treated group, the median tim
censored for the analysis. Censored observations are in
TRC-treated group were 32 at day 0 and 29 at day 100
risk in the control group were 14 at day 0 and 8 at day 1
Fig 5. Complete wound healing rate in patients completing 12-
months of follow-up at 6- and 12-month time points. There was
no statistical difference between control and tissue repair cell
(TRC)-patient groups at the 6-month time point (P 1.00, Fisher
exact test). At the 12-month time point, the greater incidence of
wound healing in the TRC-treated group was also not statistically
significant, due to the small sample size (P .61, Fisher exact test).delivered at the point of contact without the need for additional procedures such as bone marrow harvest.
otential disadvantages include concern over off-target
ngiogenesis with resultant progression of proliferative
etinopathy and occult tumor growth.
Stem cell therapy using autologous stem cells is a newly
eveloping therapy. Intra-arterial delivery18 has been inves-
igated as well as intramuscular injection. Potential tech-
iques to deliver the autologous stem cells in sufficient
umbers include direct bone marrow harvest and cell sep-
ration using a centrifuge at the point of treatment,6,19,20
one marrow mobilization using GM-CSF followed by
lasmapheresis,21 and the technique as described in this
eport in which cells are expanded within a bioreactor.
verall, there are fewer concerns with cell therapy regard-
ng the risk of off-target angiogenesis compared with gene
herapy. Potential advantages of the cell expansion tech-
ique reported here include the need to collect a relatively
mall amount of bone marrow under local anesthesia. Al-
ernative techniques require harvesting up to 500 to 600
L of bone marrow under general anesthesia. Other po-
ential advantages of TRCs are that the expansion process
nriches for the cell lineages thought to be important for
ngiogenesis and neovascularization and may reverse the
uppressive effects of chronic medical conditions on bone
arrow progenitors that may impair their regenerative
unction.9
A potential weakness of the current report is the rela-
ively small number of patients assessed in the interim
. Most events occurred in control group patients within
ched, with 7 of 14 patients censored for the analysis. In
treatment failure was not reached, with 25 of 32 patients
d by “” symbols. Number of subjects at risk in the
0 at day 200 and 16 at day 300. Number of subjects at
d 8 at day 200 and 6 at day 300.rvival
t rea
e to
dicate
and 2nalysis. This has limited the ability to perform an in-depth
11
1
1
1
1
1
1
1
1
2
2
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of which are hemodynamic measures. Although all patients
had a toe pressure, ABI, or waveform at baseline, many
patients could not have repeat studies due to digital ampu-
tation or calcified tibial arteries. As such there are insuffi-
cient numbers of patients with quantifiable hemodynamic
measures to analyze these data.
In conclusion, interim analysis of 46 of 86 patients in
RESTORE-CLI has demonstrated that intramuscular in-
jection of bone marrow-derived TRCs is safe and well
tolerated, and has demonstrated a significant improvement
in amputation-free survival and time to first occurrence of
treatment failure when compared with control subjects.
These interim results suggest TRCs may be a future poten-
tial option for the treatment of CLI patients without revas-
cularization alternatives. Based on these data, a larger piv-
otal trial evaluating the effect of TRCs on amputation-free
survival in no-option CLI patients is planned.
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